{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chaudhary R"],"funding":["National Cancer Institute (NCI)","Florida Department of Health (DOH)","NIDCR NIH HHS","National Institute of Dental and Craniofacial Research (NIDR)","National Cancer Institute","NCI NIH HHS","National Institute of Dental and Craniofacial Research","Florida Department of Health"],"pagination":["501-515"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12667737"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(3)"],"pubmed_abstract":["Purpose
We report long-term survival and comprehensive molecular biomarker analyses of a phase II trial evaluating the combination of cetuximab and nivolumab in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).Patients and methods
The long-term follow-up data were obtained from a phase II trial (NCT03370276). Archived tumors and serially collected plasma cell-free DNA were characterized by comprehensive genomic analyses. Immune markers were measured in tumor cores and margins by multiplex IHC.Results
At a median follow-up of 47.4 months, the median overall survival (OS) and 2-year OS rate were 12.7 months and 32% in all evaluable patients (n = 88) and 17.5 months and 35% in patients who had no prior therapy for R/M HNSCC (n = 43). The "],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer."],"pmcid":["PMC12667737"],"funding_grant_id":["P30-CA076292","James and Esther King Biomedical Research Grant (21K04)","P30 CA076292","R01 DE030508","R01DE030493","R01 DE030493"],"pubmed_authors":["Li J","Chaudhary R","Getz G","Chung CH","Kirtane K","Amelio AL","Moorhead G","Park R","Biernacki MI","Guevara-Patino JA","Tan A","Hernandez-Prera J","Rocco JW","Bonomi M","Slebos RJC","Meshkovska Y","Freeman SS","Saba NF","Schell MJ","Danysh BP","Song X","Thatikonda S","Haradhvala NJ"],"additional_accession":[]},"is_claimable":false,"name":"Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer.","description":"Purpose
We report long-term survival and comprehensive molecular biomarker analyses of a phase II trial evaluating the combination of cetuximab and nivolumab in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).Patients and methods
The long-term follow-up data were obtained from a phase II trial (NCT03370276). Archived tumors and serially collected plasma cell-free DNA were characterized by comprehensive genomic analyses. Immune markers were measured in tumor cores and margins by multiplex IHC.Results
At a median follow-up of 47.4 months, the median overall survival (OS) and 2-year OS rate were 12.7 months and 32% in all evaluable patients (n = 88) and 17.5 months and 35% in patients who had no prior therapy for R/M HNSCC (n = 43). The ","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-15T06:57:35.091Z","creation":"2026-06-30T03:34:32.895Z"},"accession":"S-EPMC12667737","cross_references":{"pubmed":["41117857"],"doi":["10.1158/1078-0432.CCR-25-2201","10.1158/1078-0432.ccr-25-2201"]}}